Oncology pathway explorer
Estrogen receptor
Scientific explanation
ERα (ESR1) drives a large fraction of breast cancers via genomic and non-genomic signalling. ESR1 mutations and growth-factor crosstalk contribute to endocrine resistance.
Cancers where relevant
Compounds that intersect this pathway
Selective estrogen- modulator that antagonizes ERα-driven in breast epithelium while retaining partial activity in some other tissues.
Evidence in mapped cancers: Established Oncology Use · Clinical / Human Evidence
Convergence partners
Other pathways that co-occur with Estrogen receptor on mapped adjunct records: Apoptosis.
This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.